Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
20 August 2024 - 9:35PM
UK Regulatory
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 20 August 2024 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Sylvie Louise Grégoire |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Member of the Board of Directors |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,
type of instrument, |
ADRs
|
|
|
|
Identification code |
NVO |
|
|
b) |
Nature of the transaction |
Purchase of ADRs |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 913.15 |
2 ADRs |
|
|
|
|
DKK 913.05 |
200 ADRs |
|
|
|
|
DKK 912.75 |
1 ADRs |
|
|
|
|
DKK 912.68 |
431 ADRs |
|
|
|
|
DKK 912.61 |
232 ADRs |
|
|
|
|
DKK 912.55 |
379 ADRs |
|
|
|
|
DKK 912.34 |
255 ADRs |
|
|
|
d) |
Aggregated information
|
1,500 ADRs
DKK 1,368,944.39 |
|
|
e) |
Date of the transaction |
2024-08-19 |
|
|
f) |
Place of the transaction |
New York Stock Exchange |
|
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 69,000 people in 80 countries and
markets its products in around 170 countries. Novo Nordisk's B
shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are
listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
|
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Sina
Meyer
+45 3079 6656 azey@novonordisk.com
|
Mark
Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com
|
Ida Schaap
Melvold
+45 3077 5649
idmg@novonordisk.com |
Frederik
Taylor Pitter
+45 3075 8259 fptr@novonordisk.com |
Company announcement no 65 / 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Okt 2023 bis Okt 2024
